Declining incidence of AIDS dementia complex after introduction of zidovudine treatment - Test2 - elhamkhani - TriplyDB

Declining incidence of AIDS dementia complex after introduction of zidovudine treatment

Declining incidence of AIDS dementia complex after introduction of zidovudine treatment

http://www.wikidata.org/entity/Q28341520

about

sameAs

Pathogenesis of human immunodeficiency virus infection Factors in AIDS dementia complex trial design: results and lessons from the abacavir trial Anti-human immunodeficiency virus type 1 activities of U-90152 and U-75875 in human brain cell cultures The pathogenesis of the neurological complications of HIV-1 infection.Lessons learned developing a diagnostic tool for HIV-associated dementia feasible to implement in resource-limited settings: pilot testing in Kenya.Antiretroviral treatment of central nervous system HIV-1 infection: a review.Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients.HIV effects on age-associated neurocognitive dysfunction: premature cognitive aging or neurodegenerative disease?Pharmacokinetics and pharmacodynamics of granulocyte-macrophage colony-stimulating factor and zidovudine in patients with AIDS and severe AIDS-related complex.Neuropsychological aspects of HIV infection.Risk of HIV dementia and opportunistic brain disease in AIDS and zidovudine therapy.Human immunodeficiency virus type 1 infection of the brain.Psychiatry Central nervous system targeting of 2',3'-dideoxyinosine via adenosine deaminase-activated 6-halo-dideoxypurine prodrugs Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy.Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively.HIV-related neurocognitive impairment--a review.HIV-associated neurological disorders: a guide to pharmacotherapy.Genotypical diversity of HIV clades and central nervous system impairment.Association between Plasma Homocysteine Levels and Neuronal Injury in HIV Infection.The use of methylphenidate for cognitive decline associated with HIV disease.No support for premature central nervous system aging in HIV-1 when measured by cerebrospinal fluid phosphorylated tau (p-tau).Neurologic manifestations of HIV infection. Using imaging studies and antiviral therapy effectively.Zidovudine in AIDS dementia complex.Zidovudine in asymptomatic HIV infection: knowledge and uncertainty.Pharmacokinetics of hydroxyurea in plasma and cerebrospinal fluid of HIV-1-infected patients.Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.No Neurocognitive Advantage for Immediate Antiretroviral Treatment in adults with greater than 500 CD4+ T Cell Counts.Trends and survival for AIDS patients presenting with indicative neurologic diseases.Impact of current antiretroviral therapies on neuroAIDS

P2860

Q24634681-B607007B-9660-416B-A23D-04F1D03B253D Q28469174-BCCF3B33-0096-4FA3-A697-143E335D364D Q33761961-B6F4D3B7-A836-4360-9834-4982635BEA0E Q33934512-2B38E9CB-1EE1-4FF9-BD2C-FBC0F56B1369 Q34193503-712B423C-B540-48FB-9A5E-8F1F851913E2 Q34459372-DFB93499-413D-42C9-BFDE-EB23B05A55BD Q35093695-4AB9D1D9-2E6A-409F-8C89-A86DAEFAE749 Q35276630-50A08726-9E68-4736-AA95-42383FF6B7B2 Q35810392-5F9CFC20-6710-4E75-8480-AD49FBE1A959 Q35996765-1764EFC6-25A5-441E-9505-3C9478F0ED49 Q36318432-F2311C19-D695-4AB0-888E-4EEC49D5DF9A Q36640545-31FF96B2-A88F-42F4-BEE1-4D3F110A0DFC Q36718237-E08D0967-D4D6-4D6C-9EC6-3F5D2E66869B Q36757759-1AFADE6B-A053-4A05-8DE5-E272565A724D Q37066971-075A5B02-882F-4386-8FF8-C13B17BA317E Q37374348-2D923B71-B8F5-4A29-AB1B-2C1E26CC09BA Q37899895-63535932-4710-4DBB-96D0-5E7194444539 Q37971469-2F833904-D47B-48AD-8850-3D1053A04B75 Q37980665-6E6236EF-D863-4149-8730-C36D3DD933DF Q38379162-B343A91B-296A-4DD8-86AB-7461D40DA0A7 Q40468179-F739FB4C-EE3E-4705-97AB-B2C5B36C574A Q40607244-05437D5A-EB2D-4A44-AAEC-19453900C206 Q41728204-464435A2-C9A7-4FE4-B56C-03186B6601E6 Q42877932-327EDFB8-1681-4765-B631-8FA182F815EF Q43889558-E6256E5C-0AA1-46DB-A6E2-FBDEBAFB6974 Q44582907-BE269234-B9A1-4941-9D61-1058F4864C3F Q46374842-5D8BFB3B-2600-413C-A3A2-CBBA17D9CD0D Q50051625-C5C16F5A-8792-4740-B9B6-AE5643C0BB3C Q54088085-170095F1-BF65-4966-82DF-868E26DE58CC Q57831860-4E03FD8C-0F64-4104-8D5D-C77BB9E14926

P2860

Declining incidence of AIDS dementia complex after introduction of zidovudine treatment

http://www.wikidata.org/entity/Q28341520

description

1989 nî lūn-bûn

@nan

1989 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

1989 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

1989年の論文

@ja

1989年論文

@yue

1989年論文

@zh-hant

1989年論文

@zh-hk

1989年論文

@zh-mo

1989年論文

@zh-tw

1989年论文

@wuu

name

Declining incidence of AIDS dementia complex after introduction of zidovudine treatment

@ast

Declining incidence of AIDS dementia complex after introduction of zidovudine treatment

@en

Declining incidence of AIDS dementia complex after introduction of zidovudine treatment

@nl

type

label

Declining incidence of AIDS dementia complex after introduction of zidovudine treatment

@ast

Declining incidence of AIDS dementia complex after introduction of zidovudine treatment

@en

Declining incidence of AIDS dementia complex after introduction of zidovudine treatment

@nl

prefLabel

Declining incidence of AIDS dementia complex after introduction of zidovudine treatment

@ast

Declining incidence of AIDS dementia complex after introduction of zidovudine treatment

@en

Declining incidence of AIDS dementia complex after introduction of zidovudine treatment

@nl

P1433

Q28341520-507064DC-2A3F-4574-A323-EF4C02D4BC17

P1476

Q28341520-C4C75B9D-7546-4F92-B581-82BD78ECC3B9

P2093

Q28341520-0CAB54E7-4816-4633-B9C5-81EC0F8AB12C

Q28341520-0E70C3E7-28CA-4A1B-B4A7-06B426C40008

Q28341520-2812971A-9036-48A1-B1FC-554723087EFF

Q28341520-3E84DD69-0512-4760-AC87-D612077EF2D5

Q28341520-424A202C-3C3F-47CF-9D92-928230B396D7

Q28341520-478D7CCC-0A90-4A11-9CE7-2CA0E89403B4

Q28341520-494983D3-451D-46B1-8A5B-BA372B0522C4

Q28341520-B0F4E058-575B-4B78-98AD-E23E0CEC7E39

P2860

Q28341520-029A3383-57A6-4A03-B720-B8FB662076C9

Q28341520-0BA0B791-71D1-40B1-87E3-388525589AB8

Q28341520-2B8AF572-5D57-42BC-A3AE-323898FCB8E3

Q28341520-30054FDD-197C-4574-8882-1CFA160A81CC

Q28341520-3DE70FEF-B48A-4051-A3B4-962E9AD34FCC

Q28341520-52B5E488-7EB2-4E10-AFBF-EC37AFF8672D

Q28341520-660DB141-7928-41EA-A5CD-7980400362E1

Q28341520-68A8AF59-1CC7-4171-928F-7DC7BCCFFEF1

Q28341520-695C0F6D-845C-4526-9AF3-1306881F8F40

Q28341520-7912DE2D-BA6B-41BD-9C24-81B731336DB2

P304

Q28341520-DD5DCA61-AE52-471D-9666-18C07A13BF8C

P31

Q28341520-2257F8AF-8266-444B-B0B5-FFBBFB4F86FF

P3181

Q28341520-B40E4852-B1FE-4264-B3B4-E33EDDDE1AAB

P356

Q28341520-E88BF8B6-B3FC-46D7-8850-52FEB28A97EB

P407

Q28341520-6D0A3496-E2AD-48DC-BCE3-78DAC0AD0085

P433

Q28341520-9EFF5FE9-263C-4118-A599-7D4E814D3AF1

P478

Q28341520-C5EF4F16-7332-4D27-9D33-AE808DA83CE3

P577

Q28341520-4B4F9FDD-9E3F-4450-84A4-AE10FE994928

P5875

Q28341520-DB909D37-7956-4235-AD50-13988442BCA0

P698

Q28341520-C4D5E429-02DC-46A8-9E51-55E1E4E01CEE

P921

Q28341520-070605A9-341F-4C40-84E2-888358D29A68

Q28341520-A114F805-BAAF-4026-ACBE-13D028CA2C92

P932

Q28341520-C8AD5A6A-4B15-4934-9411-080188E1B0C9

P3181

P356

BMJ.299.6703.819

P1433

P1476

Declining incidence of AIDS dementia complex after introduction of zidovudine treatment

@en

P2093

H Speelman

http://www.w3.org/2001/XMLSchema#string

J Goudsmit

http://www.w3.org/2001/XMLSchema#string

J M Lange

http://www.w3.org/2001/XMLSchema#string

J de Gans

http://www.w3.org/2001/XMLSchema#string

M Bakker

http://www.w3.org/2001/XMLSchema#string

M M Derix

http://www.w3.org/2001/XMLSchema#string

P Portegies

http://www.w3.org/2001/XMLSchema#string

S A Danner

http://www.w3.org/2001/XMLSchema#string

P2860

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients.

The human immunodeficiency virus: infectivity and mechanisms of pathogenesis.

Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS

Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex.

Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients.

The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex.

Decline of HIV antigen levels in cerebrospinal fluid during treatment with low-dose zidovudine.

Response of human-immunodeficiency-virus-associated neurological disease to 3'-azido-3'-deoxythymidine.

Hypothesis: AIDS encephalopathy is due to primary and persistent infection of the brain with a human retrovirus of the lentivirus subfamily.

P304

819-21

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4465171

http://www.w3.org/2001/XMLSchema#string

P356

10.1136/BMJ.299.6703.819

http://www.w3.org/2001/XMLSchema#string

P407

P433

6703

http://www.w3.org/2001/XMLSchema#string

P478

299

http://www.w3.org/2001/XMLSchema#string

P577

1989-09-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

20644985

http://www.w3.org/2001/XMLSchema#string

P698

2510843

http://www.w3.org/2001/XMLSchema#string

P921

P932

1837716

http://www.w3.org/2001/XMLSchema#string